Wat is de prijs voor Fresh Tracks Therapeutics, Inc. (FRTX)

Het prijs van Fresh Tracks Therapeutics, Inc. (FRTX) is $0.94

Wat is de marktkapitalisatie voor Fresh Tracks Therapeutics, Inc. (FRTX)

Marktkapitalisatie voorFresh Tracks Therapeutics, Inc. (FRTX) is $2.73M

Fresh Tracks Therapeutics, Inc. (FRTX) K/O-verhouding

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

Jaar	P/S-ratio	Wijzigen
2026 (TTM)	0.70	7.32%
2023	0.65	7.02%
2022	0.61	-98.67%
2021	45.72	335.70%
2020	10.49	1,732.14%
2019	0.57	-96.40%
2018	15.89	806.28%
2017	1.75	10.56%
2016	1.59	-11.68%
2015	1.80	-70.69%
2014	6.13	-53.86%
2013	13.28	-7.02%
2012	14.28	34.94%
2011	10.58	-24.05%
2010	13.93	14.10%
2009	12.21	72.88%
2008	7.06	-76.63%
2007	30.22	120.36%
2006	13.71	59.43%
2005	8.60	17.29%
2004	7.33	-40.07%
2003	12.24	23.06%
2002	9.94	-53.91%
2001	21.57	-53.29%
2000	46.18	0.00%

Jaar

P/S-ratio

Wijzigen

2026 (TTM)

0.70

7.32%

2023

0.65

7.02%

2022

0.61

-98.67%

2021

45.72

335.70%

2020

10.49

1,732.14%

2019

0.57

-96.40%

2018

15.89

806.28%

2017

1.75

10.56%

2016

1.59

-11.68%

2015

1.80

-70.69%

2014

6.13

-53.86%

2013

13.28

-7.02%

2012

14.28

34.94%

2011

10.58

-24.05%

2010

13.93

14.10%

2009

12.21

72.88%

2008

7.06

-76.63%

2007

30.22

120.36%

2006

13.71

59.43%

2005

8.60

17.29%

2004

7.33

-40.07%

2003

12.24

23.06%

2002

9.94

-53.91%

2001

21.57

-53.29%

2000

46.18

0.00%

Bedrijf	P/S-ratio	Verschil in P/S-ratio	Land
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	1,357.54%	US
Argenx SE ARGX.US	10.13	1,352.02%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	4.74	579.83%	BE

Bedrijf

P/S-ratio

Verschil in P/S-ratio

Land